KUALA LUMPUR, 19 April 2026 — Moirai Tech, together with KL Wellness City, the Faculty of Applied Sciences of AIMST University, and Luxe’s Clinics, held a public announcement on the advancement of Hematopoietic Stem Cell (HSC) research and CRISPR technology in Acute Myeloid Leukaemia (AML), marking an important step toward future precision medicine, regenerative science, and AI-driven healthcare innovation in Malaysia.
The event brought together leaders from medicine, biotechnology, academia, wellness healthcare, and artificial intelligence, reflecting a growing national effort to push the boundaries of modern medicine beyond conventional treatment models.
The announcement was graced by honourable guests including Dato’ Dr. Mah Hang Soon, former Deputy Minister of Education; Prof. Lee Su Yin, Dean of the Faculty of Applied Sciences, AIMST University; and Mr. Maheswaran Solayappan, who each gave strong acknowledgement to Moirai’s continuing effort in advancing medical innovation, translational research, and future healthcare development.
In her address, Prof. Lee Su Yin highlighted the importance of scientific collaboration, academic support, and research-driven innovation in shaping the next era of healthcare. She recognised the significance of building bridges between universities, medical practitioners, scientists, and technology companies, noting that meaningful healthcare breakthroughs require persistence, proper research direction, and a shared commitment to improving patient outcomes.
The event placed special focus on the potential of HSC stem cell platforms and CRISPR-based technology in the future management of AML, one of the most aggressive blood cancers. While the field remains highly specialised and requires careful clinical validation, regulatory compliance, and long-term safety monitoring, the announcement reflected a bold translational vision: to explore how stem cell science, gene-editing technology, and medical AI may one day work together to support more personalised and targeted treatment pathways.
Moirai Tech also shared its broader medical AI development roadmap, including its vision and mission statement:
“To redefine the future of healthcare by weaving compassionate, predictive AI into the fabric of clinical practice—ensuring safer pregnancies, proactive wellness, and a personalized health journey for all.”
The company outlined several key pillars of its AI healthcare ecosystem, including predictive diagnostics, human-centred design, and an integrated digital health platform combining the Moirai Smartwatch, Moirai Momcare, and Moirai Aicare. These tools are designed to support maternal health monitoring, fetal growth prediction, chronic disease risk awareness, endometriosis management, and broader preventive wellness.
Moirai’s approach emphasises that medical AI should not replace the human doctor, but rather strengthen clinical decision-making through earlier warning signs, continuous monitoring, and more personalised care. This aligns with the company’s principle of “compassionate design” — technology built not only for data, but for patients, families, and clinicians facing real-life medical uncertainty.
KL Wellness City’s participation further reinforced the importance of creating a healthcare environment where clinical services, innovation, wellness, rehabilitation, and medical research can grow together. Luxe’s Clinics also formed part of the collaborative ecosystem, supporting the translation of advanced wellness, regenerative, and aesthetic medicine concepts into practical clinical pathways.
Speaking at the event, the honoured guests acknowledged Moirai’s courage in pursuing difficult frontiers — from AI-powered maternal and general health monitoring to biotechnology research involving stem cells, CRISPR, and future precision medicine. Their recognition served as an important encouragement for continued collaboration between private innovators, academic institutions, clinicians, and healthcare stakeholders.
The 19 April announcement was not merely a product showcase, but a statement of intent: that Malaysia has the potential to participate meaningfully in the future of medical AI, regenerative medicine, and gene-based therapeutic research.
As healthcare moves into an era where diagnosis must become earlier, treatment more personalised, and monitoring more continuous, Moirai Tech aims to position itself at the intersection of medicine, artificial intelligence, biotechnology, and compassionate patient care.
The event concluded with a call for stronger collaboration among universities, clinicians, researchers, healthcare institutions, investors, and policymakers to support responsible innovation — ensuring that tomorrow’s medical breakthroughs are built with scientific integrity, ethical responsibility, and human dignity at their core.
